EBS
Price
$6.99
Change
-$0.12 (-1.69%)
Updated
Jul 3 closing price
Capitalization
120.07M
38 days until earnings call
MKGAF
Price
$134.87
Change
+$0.16 (+0.12%)
Updated
Jul 3 closing price
Capitalization
76.59B
Interact to see
Advertisement

EBS vs MKGAF

Header iconEBS vs MKGAF Comparison
Open Charts EBS vs MKGAFBanner chart's image
Emergent Biosolutions
Price$6.99
Change-$0.12 (-1.69%)
Volume$917.38K
Capitalization120.07M
Merck KGaA
Price$134.87
Change+$0.16 (+0.12%)
Volume$123
Capitalization76.59B
EBS vs MKGAF Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. MKGAF commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Buy and MKGAF is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (EBS: $6.99 vs. MKGAF: $134.87)
Brand notoriety: EBS and MKGAF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 72% vs. MKGAF: 8%
Market capitalization -- EBS: $120.07M vs. MKGAF: $76.59B
EBS [@Pharmaceuticals: Other] is valued at $120.07M. MKGAF’s [@Pharmaceuticals: Other] market capitalization is $76.59B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileMKGAF’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • MKGAF’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 3 TA indicator(s) are bullish while MKGAF’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 3 bullish, 3 bearish.
  • MKGAF’s TA Score: 5 bullish, 1 bearish.
According to our system of comparison, MKGAF is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а +2.34% price change this week, while MKGAF (@Pharmaceuticals: Other) price change was +4.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.13%. For the same industry, the average monthly price growth was +3.08%, and the average quarterly price growth was +93.03%.

Reported Earning Dates

EBS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.13% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($76.6B) has a higher market cap than EBS($120M). MKGAF has higher P/E ratio than EBS: MKGAF (20.96) vs EBS (17.73). MKGAF YTD gains are higher at: -11.015 vs. EBS (-26.883). MKGAF has higher annual earnings (EBITDA): 6.45B vs. EBS (-518.2M). MKGAF has more cash in the bank: 1.72B vs. EBS (112M). EBS has less debt than MKGAF: EBS (860M) vs MKGAF (10.6B). MKGAF has higher revenues than EBS: MKGAF (22.3B) vs EBS (1.02B).
EBSMKGAFEBS / MKGAF
Capitalization120M76.6B0%
EBITDA-518.2M6.45B-8%
Gain YTD-26.883-11.015244%
P/E Ratio17.7320.9685%
Revenue1.02B22.3B5%
Total Cash112M1.72B7%
Total Debt860M10.6B8%
FUNDAMENTALS RATINGS
EBS vs MKGAF: Fundamental Ratings
EBS
MKGAF
OUTLOOK RATING
1..100
711
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9469
PRICE GROWTH RATING
1..100
4861
P/E GROWTH RATING
1..100
1185
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (29) in the null industry is in the same range as EBS (57) in the Biotechnology industry. This means that MKGAF’s stock grew similarly to EBS’s over the last 12 months.

MKGAF's Profit vs Risk Rating (88) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that MKGAF’s stock grew similarly to EBS’s over the last 12 months.

MKGAF's SMR Rating (69) in the null industry is in the same range as EBS (94) in the Biotechnology industry. This means that MKGAF’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (48) in the Biotechnology industry is in the same range as MKGAF (61) in the null industry. This means that EBS’s stock grew similarly to MKGAF’s over the last 12 months.

EBS's P/E Growth Rating (11) in the Biotechnology industry is significantly better than the same rating for MKGAF (85) in the null industry. This means that EBS’s stock grew significantly faster than MKGAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSMKGAF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
62%
Momentum
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
67%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
65%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 3 days ago
61%
Declines
ODDS (%)
Bearish Trend 19 days ago
89%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 3 days ago
76%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALFVY42.870.08
+0.19%
Alfa-Laval AB
BHOOY5.75N/A
N/A
Boohoo Group Plc
CDBMF0.53N/A
N/A
Cordoba Minerals Corp.
FRTAY18.03N/A
N/A
Freenet AG
REOP36.00N/A
N/A
Reo Plastics, Inc.

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+0.12%
MKKGY - MKGAF
49%
Loosely correlated
-1.90%
AQST - MKGAF
19%
Poorly correlated
+1.09%
INDV - MKGAF
17%
Poorly correlated
N/A
EVO - MKGAF
17%
Poorly correlated
-3.23%
EBS - MKGAF
16%
Poorly correlated
-1.69%
More